Zenas BioPharma (ZBIO), which recently debuted on the Nasdaq, has lost over 66% of its share value, falling from a high of $26.25, recorded in October, to around $8.
The company's lead drug candidate is Obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb, to inhibit the activity of cells involved in various autoimmune diseases, without depleting them.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.